These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 35236531)
1. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. McIntyre RS; Citrome L; Cummings H; Todtenkopf MS; Tan LA; White M; Akerman S CNS Spectr; 2023 Jun; 28(3):288-299. PubMed ID: 35236531 [TBL] [Abstract][Full Text] [Related]
2. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations. Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421 [TBL] [Abstract][Full Text] [Related]
3. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646 [TBL] [Abstract][Full Text] [Related]
4. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain. Corrao MM; Nelson LA CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903 [TBL] [Abstract][Full Text] [Related]
5. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818 [TBL] [Abstract][Full Text] [Related]
6. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. Gao J; Li J; Lu X; Yang J Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507 [TBL] [Abstract][Full Text] [Related]
8. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894 [TBL] [Abstract][Full Text] [Related]
9. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used? Faden J; Serdenes R; Citrome L Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374 [TBL] [Abstract][Full Text] [Related]
10. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. Wang D; Sun X; Sadee W J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582 [TBL] [Abstract][Full Text] [Related]
11. The effect of kappa opioid receptor antagonism on energy expenditure in the obese Zucker rat. Jarosz PA Biol Res Nurs; 2007 Apr; 8(4):294-9. PubMed ID: 17456590 [TBL] [Abstract][Full Text] [Related]
13. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. Tek C; Guloksuz S; Srihari VH; Reutenauer EL BMC Psychiatry; 2013 Jun; 13():176. PubMed ID: 23805859 [TBL] [Abstract][Full Text] [Related]
14. Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder. Med Lett Drugs Ther; 2021 Nov; 63(1638):191-192. PubMed ID: 35085217 [No Abstract] [Full Text] [Related]
15. Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats. Kurbanov DB; Currie PJ; Simonson DC; Borsook D; Elman I J Psychopharmacol; 2012 Sep; 26(9):1244-51. PubMed ID: 22723540 [TBL] [Abstract][Full Text] [Related]
16. Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. Baptista T; Lacruz A; Acosta A; Colasante C; de Quijada M; de Mendoza S; Mendoza JM; Hernández L Appetite; 2000 Feb; 34(1):77-86. PubMed ID: 10744894 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. Tek C; Ratliff J; Reutenauer E; Ganguli R; O'Malley SS J Clin Psychopharmacol; 2014 Oct; 34(5):608-12. PubMed ID: 25102328 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012 [TBL] [Abstract][Full Text] [Related]
20. Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade. Trøstheim M; Eikemo M; Haaker J; Frost JJ; Leknes S Neuropsychopharmacology; 2023 Jan; 48(2):299-307. PubMed ID: 35978096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]